Analysing the SLC25A32 protein expression level data from the CPTAC database in the UALCAN platform revealed that SLC25A32 protein expression increased over SLC25A32 in OV, UCEC, lung cancer, HNSC, and liver cancer and decreased over SLC25A32 in PAAD and glioblastoma (Figures 4(a) and 4(d)). This evidence concerns the gene SLC25A32 and pancreatic adenocarcinoma.